{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:07:31Z","timestamp":1775135251028,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,2]]},"DOI":"10.7759\/cureus.106319","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:07:56Z","timestamp":1775131676000},"source":"Crossref","is-referenced-by-count":0,"title":["Concurrent Papillary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma Presenting With Hoarseness and Dysphagia"],"prefix":"10.7759","author":[{"given":"Sumreen","family":"Nazly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshia","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salman J","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurdeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible KC","year":"2021","unstructured":"Bible KC, Kebebew E, Brierley J, et al.. 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021, 31:337-86. 10.1089\/thy.2020.0944","journal-title":"Thyroid"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer: A review","volume":"331","author":"Boucai L","year":"2024","unstructured":"Boucai L, Zafereo M, Cabanillas ME. Thyroid cancer: A review. JAMA. 2024, 331:425-35. 10.1001\/jama.2023.26348","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin JA","year":"2016","unstructured":"Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016, 375:1054-67. 10.1056\/NEJMra1501993","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen BR","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, et al.. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016, 26:1-133. 10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3362","article-title":"Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019","volume":"6","author":"Maniakas A","year":"2020","unstructured":"Maniakas A, Dadu R, Busaidy NL, et al.. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncol. 2020, 6:1397-404. 10.1001\/jamaoncol.2020.3362","journal-title":"JAMA Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.76","article-title":"Anaplastic thyroid carcinoma: From clinicopathology to genetics and advanced therapies","volume":"13","author":"Molinaro E","year":"2017","unstructured":"Molinaro E, Romei C, Biagini A, et al.. Anaplastic thyroid carcinoma: From clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017, 13:644-60. 10.1038\/nrendo.2017.76","journal-title":"Nat Rev Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00020-X","article-title":"Thyroid cancer","volume":"401","author":"Chen DW","year":"2023","unstructured":"Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR. Thyroid cancer. Lancet. 2023, 401:1531-44. 10.1016\/S0140-6736(23)00020-X","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.75","article-title":"Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: Identification of TERT mutation as an independent risk factor for transformation","volume":"30","author":"Oishi N","year":"2017","unstructured":"Oishi N, Kondo T, Ebina A, et al.. Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: Identification of TERT mutation as an independent risk factor for transformation. Mod Pathol. 2017, 30:1527-37. 10.1038\/modpathol.2017.75","journal-title":"Mod Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0500","article-title":"The 2017 Bethesda System for reporting thyroid cytopathology","volume":"27","author":"Cibas ES","year":"2017","unstructured":"Cibas ES, Ali SZ. The 2017 Bethesda System for reporting thyroid cytopathology. Thyroid. 2017, 27:1341-6. 10.1089\/thy.2017.0500","journal-title":"Thyroid"},{"key":"ref10","article-title":"AJCC Cancer Staging Manual","author":"Amin MB","year":"2017","unstructured":"Amin MB, Edge SB, Greene FL, et al.. AJCC Cancer Staging Manual. Springer, New York, NY; 2017."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12553-6","article-title":"Coexisting papillary and anaplastic thyroid cancer: Elucidating the spectrum of aggressive behavior","volume":"30","author":"Greenberg JA","year":"2023","unstructured":"Greenberg JA, Moore MD, Thiesmeyer JW, et al.. Coexisting papillary and anaplastic thyroid cancer: Elucidating the spectrum of aggressive behavior. Ann Surg Oncol. 2023, 30:137-45. 10.1245\/s10434-022-12553-6","journal-title":"Ann Surg Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy123","article-title":"Early evolutionary divergence between papillary and anaplastic thyroid cancers","volume":"29","author":"Capdevila J","year":"2018","unstructured":"Capdevila J, Mayor R, Mancuso FM, et al.. Early evolutionary divergence between papillary and anaplastic thyroid cancers. Ann Oncol. 2018, 29:1454-60. 10.1093\/annonc\/mdy123","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa I","year":"2016","unstructured":"Landa I, Ibrahimpasic T, Boucai L, et al.. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016, 126:1052-66. 10.1172\/JCI85271","journal-title":"J Clin Invest"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: Updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah V","year":"2022","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, et al.. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: Updated analysis from the phase II ROAR basket study. Ann Oncol. 2022, 33:406-15. 10.1016\/j.annonc.2021.12.014","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.06.044","article-title":"Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)","volume":"173","author":"Higashiyama T","year":"2022","unstructured":"Higashiyama T, Sugino K, Hara H, et al.. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). Eur J Cancer. 2022, 173:210-8. 10.1016\/j.ejca.2022.06.044","journal-title":"Eur J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks C","year":"2021","unstructured":"Dierks C, Seufert J, Aumann K, et al.. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. 2021, 31:1076-85. 10.1089\/thy.2020.0322","journal-title":"Thyroid"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/473916-concurrent-papillary-thyroid-carcinoma-and-anaplastic-thyroid-carcinoma-presenting-with-hoarseness-and-dysphagia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:07:57Z","timestamp":1775131677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/473916-concurrent-papillary-thyroid-carcinoma-and-anaplastic-thyroid-carcinoma-presenting-with-hoarseness-and-dysphagia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.106319","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,2]]}}}